X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net procees will be used for the clinical development of LBS-008 (tinlarebant), a novel, once-a-day oral therapy which is intended to reduce the accumulation of toxins in the eye that cause Stargardt Disease (STGD1) and contribute to GA, or advanced dry AMD.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 25, 2024
Details:
LBS-008 (tinlarebant) is a novel Retinol-binding protein 4 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of Stargardt Disease.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
LBS-008 (tinlarebant) is a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced Dry AMD.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
LBS-008 (tinlarebant) is an orally administered tablet, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Belite Bio intends to use the net proceeds of the offering for clinical trials and further clinical development of LBS-008 (tinlarebant), a novel oral therapy intended as an early intervention to prevent the accumulation of vitamin A-based toxins (bisretinoids).
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities LLC
Deal Size: $30 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 30, 2023
Details:
LBS-008 (tinlarebant) is a novel oral therapy intended as an early intervention to prevent the accumulation of vitamin A-based toxins (bisretinoids) that cause STGD1 and contribute to pathogenesis in Dry AMD.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
LBS-008 (aka Tinlarebant), is a novel oral therapy that prevents the buildup of toxins in the eye was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time point.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2022
Details:
Preliminary data from the Phase 2 trial of LBS-008 (tinlarebant) at the first 6-month interval shows that 8 of the 13 patients (or 61.5%) recorded a gain in best-corrected visual acuity (BCVA) in at least one eye, including 2 patients who recorded a BCVA gain in both eyes.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
LBS-008 (tinlarebant) is orally-available, small molecule retinol binding protein 4 antagonist that selectively reduces delivery of vitamin A (retinol) to eye, leading to a reduction of toxic vitamin A byproducts that have been implicated in the onset and progression of STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
LBS-008 (tinlarebant) is small molecule RBP4 antagonist that selectively reduces the delivery of vitamin A (retinol) to eye leading to a reduction of toxic vitamin A byproducts (bisretinoids) that have been implicated in onset and progression of STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
LBS-008 (tinlarebant) is a novel oral therapy that prevents the buildup of toxins in the eye that cause STGD1 and contribute to dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
LBS-008 (tinlarebant) is a novel oral therapy that prevents the buildup of toxins in the eye that cause STGD1 and contribute to dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Belite expects to use the net proceeds from the offering to fund the Phase 3 clinical trial of LBS-008 for STGD1, further clinical development of LBS-008 for dry AMD, working capital and other general corporate purposes.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Benchmark Company
Deal Size: $40.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 12, 2022
Details:
LBS-008 (aka Tinlarebant), is a novel oral therapy that prevents the buildup of toxins in the eye that cause STGD1 and contribute to dry AMD showed an acceptable safety profile in adolescent Stargardt disease subjects.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
Belite expects to use the net proceeds from the offering to fund the Phase 3 clinical trial of LBS-008 (Tinlarebant) for STGD1, further clinical development of LBS-008 for dry AMD, working capital and other general corporate purposes.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $36.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2022
Details:
LBS-008 (tinlarebant) is a novel oral therapy that prevents the buildup of toxins in the eye that cause STGD1 and contribute to dry AMD, works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), a carrier protein that transports retinol to the eye.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
A total of 83 subjects were administered with LBS-008 either as a single dose or repeated doses for 14 consecutive days. Both studies concluded that pharmacological doses of LBS-008 were well tolerated and that LBS-008's PK / PD profile supports daily oral administration.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: BPN-14967
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
